Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Risks of less common cancers in proven mutation carriers with lynch syndrome.

Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, Schackert HK, Goergens H, von Knebel Doeberitz M, Goecke TO, Schmiegel W, Buettner R, Moeslein G, Letteboer TG, Gómez García E, Hes FJ, Hoogerbrugge N, Menko FH, van Os TA, Sijmons RH, Wagner A, Kluijt I, Propping P, Vasen HF.

J Clin Oncol. 2012 Dec 10;30(35):4409-15. doi: 10.1200/JCO.2012.43.2278. Epub 2012 Oct 22.

PMID:
23091106
2.

Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome.

Win AK, Lindor NM, Winship I, Tucker KM, Buchanan DD, Young JP, Rosty C, Leggett B, Giles GG, Goldblatt J, Macrae FA, Parry S, Kalady MF, Baron JA, Ahnen DJ, Marchand LL, Gallinger S, Haile RW, Newcomb PA, Hopper JL, Jenkins MA.

J Natl Cancer Inst. 2013 Feb 20;105(4):274-9. doi: 10.1093/jnci/djs525. Epub 2013 Feb 5.

3.

Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.

Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Clendenning M, Rosty C, Arnold J, Levine AJ, Haile RW, Gallinger S, Le Marchand L, Newcomb PA, Hopper JL, Jenkins MA.

J Natl Cancer Inst. 2012 Sep 19;104(18):1363-72. Epub 2012 Aug 28.

4.

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.

Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ, Caron O, Colas C, Noguès C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin JC, Berthet P, Leroux D, Duffour J, Manouvrier S, Frébourg T, Sobol H, Lasset C, Bonaïti-Pellié C; French Cancer Genetics Network.

JAMA. 2011 Jun 8;305(22):2304-10. doi: 10.1001/jama.2011.743.

PMID:
21642682
5.

The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.

Watson P, Vasen HFA, Mecklin JP, Bernstein I, Aarnio M, Järvinen HJ, Myrhøj T, Sunde L, Wijnen JT, Lynch HT.

Int J Cancer. 2008 Jul 15;123(2):444-449. doi: 10.1002/ijc.23508.

6.

Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands.

Capelle LG, Van Grieken NC, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, Vasen HF, Kuipers EJ.

Gastroenterology. 2010 Feb;138(2):487-92. doi: 10.1053/j.gastro.2009.10.051. Epub 2009 Nov 10.

PMID:
19900449
7.

MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.

Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT.

J Clin Oncol. 2001 Oct 15;19(20):4074-80.

PMID:
11600610
8.

Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome.

Guindalini RS, Win AK, Gulden C, Lindor NM, Newcomb PA, Haile RW, Raymond V, Stoffel E, Hall M, Llor X, Ukaegbu CI, Solomon I, Weitzel J, Kalady M, Blanco A, Terdiman J, Shuttlesworth GA, Lynch PM, Hampel H, Lynch HT, Jenkins MA, Olopade OI, Kupfer SS.

Gastroenterology. 2015 Nov;149(6):1446-53. doi: 10.1053/j.gastro.2015.07.052. Epub 2015 Aug 3.

9.

Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.

Skeldon SC, Semotiuk K, Aronson M, Holter S, Gallinger S, Pollett A, Kuk C, van Rhijn B, Bostrom P, Cohen Z, Fleshner NE, Jewett MA, Hanna S, Shariat SF, Van Der Kwast TH, Evans A, Catto J, Bapat B, Zlotta AR.

Eur Urol. 2013 Feb;63(2):379-85. doi: 10.1016/j.eururo.2012.07.047. Epub 2012 Aug 2.

PMID:
22883484
10.

Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.

van der Post RS, Kiemeney LA, Ligtenberg MJ, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D, Schaap L, Kets CM, van Krieken JH, Hoogerbrugge N.

J Med Genet. 2010 Jul;47(7):464-70. doi: 10.1136/jmg.2010.076992.

11.

Frequent mismatch-repair defects link prostate cancer to Lynch syndrome.

Dominguez-Valentin M, Joost P, Therkildsen C, Jonsson M, Rambech E, Nilbert M.

BMC Urol. 2016 Mar 24;16:15. doi: 10.1186/s12894-016-0130-1.

12.

Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families.

Boilesen AE, Bisgaard ML, Bernstein I.

Acta Obstet Gynecol Scand. 2008;87(11):1129-35. doi: 10.1080/00016340802443806.

PMID:
18972272
13.

Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.

Plaschke J, Engel C, Krüger S, Holinski-Feder E, Pagenstecher C, Mangold E, Moeslein G, Schulmann K, Gebert J, von Knebel Doeberitz M, Rüschoff J, Loeffler M, Schackert HK.

J Clin Oncol. 2004 Nov 15;22(22):4486-94. Epub 2004 Oct 13.

PMID:
15483016
14.

Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.

Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, Buchanan DD, Clendenning M, Giles GG, Winship I, Macrae FA, Goldblatt J, Southey MC, Arnold J, Thibodeau SN, Gunawardena SR, Bapat B, Baron JA, Casey G, Gallinger S, Le Marchand L, Newcomb PA, Haile RW, Hopper JL, Jenkins MA.

J Clin Oncol. 2012 Mar 20;30(9):958-64. doi: 10.1200/JCO.2011.39.5590. Epub 2012 Feb 13.

15.

Evidence for breast cancer as an integral part of Lynch syndrome.

Buerki N, Gautier L, Kovac M, Marra G, Buser M, Mueller H, Heinimann K.

Genes Chromosomes Cancer. 2012 Jan;51(1):83-91. doi: 10.1002/gcc.20935. Epub 2011 Oct 27.

PMID:
22034109
16.

Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations.

Joost P, Therkildsen C, Dominguez-Valentin M, Jönsson M, Nilbert M.

Urology. 2015 Dec;86(6):1212-7. doi: 10.1016/j.urology.2015.08.018. Epub 2015 Sep 15.

PMID:
26385421
17.

Risk of pancreatic cancer in families with Lynch syndrome.

Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, Bandipalliam P, Stoffel EM, Gruber SB, Syngal S.

JAMA. 2009 Oct 28;302(16):1790-5. doi: 10.1001/jama.2009.1529.

18.

Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.

Ait Ouakrim D, Dashti SG, Chau R, Buchanan DD, Clendenning M, Rosty C, Winship IM, Young JP, Giles GG, Leggett B, Macrae FA, Ahnen DJ, Casey G, Gallinger S, Haile RW, Le Marchand L, Thibodeau SN, Lindor NM, Newcomb PA, Potter JD, Baron JA, Hopper JL, Jenkins MA, Win AK.

J Natl Cancer Inst. 2015 Jun 24;107(9). pii: djv170. doi: 10.1093/jnci/djv170. Print 2015 Sep.

19.

Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds.

Grindedal EM, Renkonen-Sinisalo L, Vasen H, Evans G, Sala P, Blanco I, Gronwald J, Apold J, Eccles DM, Sánchez AA, Sampson J, Järvinen HJ, Bertario L, Crawford GC, Stormorken AT, Maehle L, Moller P.

J Med Genet. 2010 Feb;47(2):99-102. doi: 10.1136/jmg.2009.068130. Epub 2009 Jul 26.

PMID:
19635727
20.

Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery.

Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church JM, Baron JA, Giles GG, Leggett BA, Winship I, Lipton L, Young GP, Young JP, Lodge CJ, Southey MC, Newcomb PA, Le Marchand L, Haile RW, Lindor NM, Gallinger S, Hopper JL, Jenkins MA.

Gut. 2011 Jul;60(7):950-7. doi: 10.1136/gut.2010.228056. Epub 2010 Dec 30.

Supplemental Content

Support Center